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Background. Recent studies have demonstrated the potential safety of percutaneous coronary interventions (PCI) for unprotected left main 
coronary artery (ULMCA) stenosis in selected populations. However, current use and outcomes of ULMCA PCI in routine clinical practice in the US is 
unclear.
Methods. Using a contemporary (2004-2008) cohort of 5,627 patients undergoing ULMCA PCI at 693 centers within the NCDR CathPCI registry, we 
evaluated temporal trends in PCI use, patient characteristics, and in-hospital mortality. We also examined 30-month death and major adverse events 
(death, MI, and revascularization) in 2,765 Medicare-linked elderly (≥65 years) patients undergoing ULMCA PCI, using inverse probability weighted 
(IPW) estimators and Cox proportional hazards models to compare outcomes following drug-eluting (DES) versus bare-metal stent (BMS) use. 
Results. Among all NCDR ULMCA disease patients (n=131,004), 5,627 (4.3%) underwent PCI. Patients undergoing PCI had higher baseline clinical 
risk and high in-hospital mortality rates (13.1% vs 4.6%, p <0.001) compared with non-stented ULMCA patients. By 30 months, 42.7% of the ULMCA 
Medicare-linked PCI cohort had died and 57.9% had at least one major adverse event. Features associated with increased unadjusted 30-month 
incidence of adverse outcomes included high clinical urgency, bifurcation lesions, pre-existing diabetes, reduced left ventricular function, racial and 
ethnic minority status, and the absence of procedural IVUS use. Major adverse events were similar among DES and BMS-treated patients (adjusted 
HR 0.95, 95% CI 0.84 to 1.06); however, patients selected for DES use experienced a lower risk of death (adjusted HR 0.84, 95% CI 0.73 to 0.96).
Conclusions. ULMCA PCI is relatively rarely performed in the United States and is reserved for those at high procedural risk. Death and major 
adverse events following percutaneous revascularization in elderly ULMCA patients are common, and influenced primarily by patient and procedural 
characteristics rather than stent type.
